Neutrophil/lymphocyte ratio as a prognostic indicator of hepatic arterial infusion chemotherapy with arterial cisplatin plus continuous 5-fluorouracil

Hepatology Research

Volumn 45, Issue 7, 2015, Pages 755-763

  Tajiri, Kazuto ^a   Kawai, Kengo ^a   Minemura, Masami ^a   Yasumura, Satoshi ^a   Hosokawa, Ayumu ^a   Kawabe, Hideto ^a   Tomizawa, Gakuto ^a   Sugiyama, Toshiro ^a  

^a TOYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

5 fluorouracil; Arterial cisplatin; Hepatic arterial infusion chemotherapy; Neutrophil lymphocyte ratio

Indexed keywords

CISPLATIN; FLUOROURACIL; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTERITIS; ARTERY OCCLUSION; ARTICLE; ASCITES; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER PROGNOSIS; CANCER SURVIVAL; CATHETER OCCLUSION; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL INDICATOR; CONSERVATIVE TREATMENT; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; HYPERTRANSAMINASEMIA; LEUKOPENIA; LIVER ARTERY OCCLUSION; LIVER CELL CARCINOMA; LIVER FUNCTION; MALE; NEUTROPENIA; NEUTROPHIL LYMPHOCYTE RATIO; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; THROMBOCYTOPENIA; VERY ELDERLY; VOMITING;

EID: 84935052739     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12417     Document Type: Article

References (44)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127.
3. Llovet JM, Ricci S, Mazzaferro V etal. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
4. Cheng AL, Kang YK, Chen Z etal. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
5. Kudo M. Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. Liver Cancer 2012; 1: 62-70.
6. Nouso K, Miyahara K, Uchida D etal. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. Br J Cancer 2013; 109: 1904-1907.
7. Shao YY, Huang CC, Liang PC, Lin ZZ. Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma. Asia Pac J Clin Oncol 2010; 6: 80-88.
8. Nagano H. Treatment of advanced hepatocellular carcinoma: intraarterial infusion chemotherapy combined with interferon. Oncology 2010; 78 (Suppl 1): 142-147.
9. Ando E, Tanaka M, Yamashita F etal. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 2002; 95: 588-595.
10. Lai YC, Shih CY, Jeng CM etal. Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2003; 9: 2666-2670.
11. Kim BK, Park JY, Choi HJ etal. Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2011; 137: 659-667.
12. Eun JR, Lee HJ, Moon HJ, Kim TN, Kim JW, Chang JC. Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. Scand J Gastroenterol 2009; 44: 1477-1486.
13. Lim TY, Cheong JY, Cho SW etal. [Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis]. Korean J Hepatol 2006; 12: 65-73.
14. Ueshima K, Kudo M, Takita M etal. Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. Oncology 2012; 78 (Suppl 1): 148-153.
15. Toyoda H, Nakano S, Kumada T etal. The efficacy of continuous local arterial infusion of 5-fluorouracil and cisplatin through an implanted reservoir for severe advanced hepatocellular carcinoma. Oncology 1995; 52: 295-299.
16. Okuda K, Tanaka M, Shibata J etal. Hepatic arterial infusion chemotherapy with continuous low dose administration of cisplatin and 5-fluorouracil for multiple recurrence of hepatocellular carcinoma after surgical treatment. Oncol Rep 1999; 6: 587-591.
17. Nagamatsu H, Hiraki M, Mizukami N etal. Intra-arterial therapy with cisplatin suspension in lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis. Aliment Pharmacol Ther 2010; 32: 543-550.
18. Scanlon KJ, Newman EM, Lu Y, Priest DG. Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. Proc Natl Acad Sci U S A 1986; 83: 8923-8925.
19. Shirasaka T, Shimamoto Y, Ohshimo H, Saito H, Fukushima M. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 1993; 32: 167-172.
20. Bruix J, Sherman M, Llovet JM etal. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.
21. Zahorec R. Ratio of neutrophil to lymphocyte counts - rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 2001; 102: 5-14.
22. Xiao WK, Chen D, Li SQ, Fu SJ, Peng BG, Liang LJ. Prognostic significance of neutrophil-lymphocyte ratio in hepatocellular carcinoma: a meta-analysis. BMC Cancer 2014; 14: 117.
23. Shindoh N, Ozaki Y, Kyogoku S, Yamana D, Sumi Y, Katayama H. Stabilization of a percutaneously implanted port catheter system for hepatic artery chemotherapy infusion. Cardiovasc Intervent Radiol 1999; 22: 344-347.
24. Calabro-Jones PM, Byfield JE, Ward JF, Sharp TR. Time-dose relationships for 5-fluorouracil cytotoxicity against human epithelial cancer cells in vitro. Cancer Res 1982; 42: 4413-4420.
25. Yoshikawa M, Ono N, Yodono H, Ichida T, Nakamura H. Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res 2008; 38: 474-483.
26. Ikeda M, Okusaka T, Furuse J etal. A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer Chemother Pharmacol 2013; 72: 463-470.
27. Kim HY, Kim JD, Bae SH etal. A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma. Korean J Hepatol 2010; 16: 355-361.
28. Kirikoshi H, Yoneda M, Mawatari H etal. Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization? World J Gastroenterol 2012; 18: 1933-1939.
29. Miyaki D, Aikata H, Honda Y etal. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification. J Gastroenterol Hepatol 2012; 27: 1850-1857.
30. Niizeki T, Sumie S, Torimura T etal. Serum vascular endothelial growth factor as a predictor of response and survival in patients with advanced hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy. J Gastroenterol 2012; 47: 686-695.
31. Oh MJ, Lee HJ, Lee SH. Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy. Clin Mol Hepatol 2013; 19: 288-299.
32. Shao YY, Liang PC, Wu YM etal. A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy. Liver Int 2013; 33: 1413-1419.
33. Park JY, Ahn SH, Yoon YJ etal. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007; 110: 129-137.
34. Woo HY, Bae SH, Park JY etal. A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2010; 65: 373-382.
35. Yamasaki T, Kimura T, Kurokawa F etal. Prognostic factors in patients with advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy. J Gastroenterol 2005; 40: 70-78.
36. Zaitsu J, Yamasaki T, Saeki I etal. Serum transferrin as a predictor of prognosis for hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma. Hepatol Res 2014; 44: 481-490.
37. Mano Y, Shirabe K, Yamashita Y etal. Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis. Ann Surg 2013; 258: 301-305.
38. Harimoto N, Shirabe K, Nakagawara H etal. Prognostic factors affecting survival at recurrence of hepatocellular carcinoma after living-donor liver transplantation: with special reference to neutrophil/lymphocyte ratio. Transplantation 2013; 96: 1008-1012.
39. Huang ZL, Luo J, Chen MS, Li JQ, Shi M. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization. J Vasc Interv Radiol 2011; 22: 702-709.
40. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.
41. Svennevig JL, Lunde OC, Holter J, Bjorgsvik D. Lymphoid infiltration and prognosis in colorectal carcinoma. Br J Cancer 1984; 49: 375-377.
42. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-1570.
43. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58-62.
44. Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 2006; 312: 1171-1175.